Natural killer T cell

The term "NK T cells" was first used in mice to define a subset of T cells that expressed the natural killer (NK) cell-associated marker NK1.1 (CD161). It is now generally accepted that the term "NKT cells" refers to CD1d-restricted T cells, present in mice and humans, some of which coexpress a heavily biased, semi-invariant T-cell receptor and NK cell markers. ==Molecular characterization==

NKT cells are a subset of T cells that coexpress an αβ T-cell receptor, but also express a variety of molecular markers that are typically associated with NK cells, such as NK1.1. The best-known NKT cells differ from conventional αβ T cells in that their T-cell receptors are far more limited in diversity ('invariant' or 'type 1' NKT). They and other CD1d-restricted T cells ('type 2' NKT) recognize lipids and glycolipids presented by CD1d molecules, a member of the CD1 family of antigen-presenting molecules, rather than peptide-major histocompatibility complexes (MHCs). As such, NKT cells are important in recognizing glycolipids from organisms such as Mycobacterium, which causes tuberculosis. NKT cells include both NK1.1+ and NK1.1−, as well as CD4+, CD4−, CD8+ and CD8− cells. Natural killer T cells can share other features with NK cells, as well, such as CD16 and CD56 expression and granzyme production. Invariant natural killer T (iNKT) cells express high levels of and are dependent on the transcriptional regulator promyelocytic leukemia zinc finger for their development. ==Classification==

Classification of natural killer T cells into three groups has been proposed: == Development ==

NKT cells differentiate into effector cells in the thymus unlike conventional T cells which differentiate into effector subpopulations in secondary lymphoid organs. Following the same developmental process as T cells in the thymus, the precursor to NKT cells undergoes four double negative stages and rearranges its beta-chain at stage three. At this stage, the immature thymocytes lack both CD4 and CD8 markers. After undergoing checks for proper TCR development, they move on to double positive selection. It is believed the precursor cells to NKT cells undergo CD1d-dependent positive selection where the CD1d molecule with the lipid iGb3 interacts with the TCR of a CD4+CD8+ cell. PLZF induces cells to differentiate into iNKT cells through changing their function by the cytokines it can express. The linear differentiation model of NKT cells starts with the NKT cell precursor at stage zero where it undergoes positive selection. This model requires all NKT cells to undergo the four stages before it can terminally differentiate This pathway doesn’t require cells to undergo through the four stages of development. A population of thymic T cells before stage zero can develop into any of the three differentiated iNKT subpopulations. ==Invariant NKT (iNKT) cells==

The best-known subset of CD1d-dependent NKT cells are invariant NKT cells, also known as Type I or iNKT. This subset expresses an invariant T-cell receptor (TCR) α chain. They are notable for their ability to respond rapidly to danger signals and pro-inflammatory cytokines. Once activated, they engage in effector functions, like NK transactivation, T cell activation and differentiation, B cell activation, dendritic cell activation and cross-presentation activity, and macrophage activation. iNKT cells recognize lipid antigens presented by CD1d, a non-polymorphic major histocompatibility complex class I-like antigen presenting molecule. These cells are conserved between humans and mice. The highly conserved TCR is made of Va24-Ja18 paired with Vb11 in humans, which is specific for glycolipid antigens. The best known antigen of iNKT cells is alpha-galactosylceramide (αGalCer), which is a synthetic form of a chemical purified from the deep sea sponge Agelas mauritianus. iNKT cells develop in the thymus, and distribute to the periphery. They are most commonly found in the liver, but are also found in the thymus, spleen, peripheral blood, bone marrow and fat tissue. In comparison to mice, humans have fewer iNKT cells and have a wide variation in the amount of circulating iNKT cells. Once activated iNKT cells can impact the type and strength of an immune response. They engage in cross talk with other immune cells, like dendritic cells, neutrophils and lymphocytes. Activation occurs by engagement with their invariant TCR. iNKT cells can also be indirectly activated through cytokine signaling. They are known to play a role in chronic inflammatory diseases like autoimmune disease, asthma and metabolic syndrome. In human autoimmune diseases, their numbers are decreased in peripheral blood. It is not clear whether this is a cause or effect of the disease. Absence of microbe exposure in early development led to increased iNKT cells and immune morbidity in a mouse model. ==Function==

Upon activation, NKT cells are able to produce large quantities of interferon gamma, IL-4, and granulocyte-macrophage colony-stimulating factor, as well as multiple other cytokines and chemokines (such as IL-2, IL-13, IL-17, IL-21, and TNF-alpha). NKT cells recognize protected microbial lipid agents which are presented by CD1d-expressing antigen presenting cells. This serves as a pathway for NKT cells to fight against infections and enhance the humoral immunity. The NKT cells provide support and help to B cells which act as a microbial defense and aid in targeting for B-cell vaccines. ==Significance==

NKT cells seem to be essential for several aspects of immunity because their dysfunction or deficiency has been shown to lead to the development of autoimmune diseases such as diabetes, autoinflammatory diseases such as atherosclerosis, and cancers. NKT cells have recently been implicated in the disease progression of human asthma. The clinical potential of NKT cells lies in the rapid release of cytokines (such as IL-2, IFN-gamma, TNF-alpha, and IL-4) that promote or suppress different immune responses. Most clinical trials with NKT cells have been performed with cytokine-induced killer cells (CIK). ==See also==